Heart disease is the major cause of death across the globe. According to the World Health Organization, around 17.9 million people died from cardiovascular diseases (CVDs) in 2016, which accounted for 31% of all global deaths. 85% of these deaths are caused due to heart disease and stroke. Coronary heart disease, also called ischemic heart disease, is the most common heart problem around the world. In the past decade, significant changes in the diagnosis and surgeries of coronary artery diseases (CADs) and myocardial ischemia are undergoing major technological advancements. As a result, the global [FURL=https://www.industryarc.com/PressRelease/2001/Myocardial-Ischemia-Market-Research.html]Myocardial Ischemia Market[/FURL] was rising and attained a value of 37.5 billion in 2018. Furthermore, the demand for this market is accelerating at a CAGR of 6% during the forecast period 2019-2025.The Prominence of Research Activities in the Global Myocardial Ischemia Market
In the modern era of revascularization, major advancements are observed in the management and effective care of myocardial ischemia or cardiac ischemia and coronary artery diseases. With the improved treatment techniques, the severity and predominance of myocardial ischemia and anginal symptoms are reducing further. Coronary angiography, a standard diagnosis method of cardiac ischemia, is undergoing major research activities and clinical trials in the invasive coronary angiography and non-invasive coronary angiography techniques. Furthermore, the research activities related to these diagnosis techniques are focusing on the effective outcomes and long-term predictability of disease based on the patient’s condition.
Browse Myocardial Ischemia Market Report Link:
[FURL]https://www.industryarc.com/PressRelease/2001/Myocardial-Ischemia-Market-Research.html[/FURL]
Key Companies in the Myocardial Ischemia Market
The core companies operating with a major share in the global myocardial ischemia market are AstraZeneca plc, Taxus Cardium Pharmaceuticals, Novartis AG, Daiichi Sankyo Company Limited, ViroMed Co. Ltd., Bayer AG, Boehringer Ingelheim group, International GmbH, Boston Scientific Corporation, and Baxter International Inc. These key players are carrying out ceaseless clinical trials and drug releases, which are thriving in this market.
Talk to one of our sales representative about the full report by providing your details in the link below:
[FURL]https://www.industryarc.com/support.php?id=16119[/FURL]
About IndustryARC: IndustryARC is a research and consulting firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.